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Abstract
Background: Empyema is an increasingly frequent clinical problem worldwide, and has substantial morbidity and mortality.
Our objectives were to identify the clinical, surgical and microbiological features, and management outcomes, of empyema.
Methods: A retrospective observational study over 12 years (1999–2010) was carried out at The Heart Hospital, London,
United Kingdom. Patients with empyema were identified by screening the hospital electronic ‘Clinical Data Repository’.
Demographics, clinical and microbiological characteristics, underlying risk factors, peri-operative blood tests, treatment and
outcomes were identified. Univariable and multivariable statistical analyses were performed.
Results: Patients (n = 406) were predominantly male (74.1%); median age = 53 years (IQR = 37–69). Most empyema were
community-acquired (87.4%) and right-sided (57.4%). Microbiological diagnosis was obtained in 229 (56.4%) patients, and
included streptococci (16.3%), staphylococci (15.5%), Gram-negative organisms (8.9%), anaerobes (5.7%), pseudomonads
(4.4%) and mycobacteria (9.1%); 8.4% were polymicrobial. Most (68%) cases were managed by open thoracotomy and
decortication. Video-assisted thoracoscopic surgery (VATS) reduced hospitalisation from 10 to seven days (P= 0.0005). All-
cause complication rate was 25.1%, and 28 day mortality 5.7%. Predictors of early mortality included: older age (P= 0.006),
major co-morbidity (P= 0.01), malnutrition (P= 0.001), elevated red cell distribution width (RDW, P,0.001) and serum
alkaline phosphatase (P= 0.004), and reduced serum albumin (P= 0.01) and haemoglobin (P= 0.04).
Conclusions: Empyema remains an important cause of morbidity and hospital admissions. Microbiological diagnosis was
only achieved in just over 50% of cases, and tuberculosis is a notable causative organism. Treatment of empyema with VATS
may reduce duration of hospital stay. Raised RDW appears to associate with early mortality.
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Introduction
Thoracic empyema, defined as pus in the pleural cavity, is
associated with considerable morbidity and mortality worldwide.
A number of studies among adults and children consistently show
that its incidence continues to increase in Western countries
despite improvements in medical care and availability of effective
antimicrobial therapy [1–8]. Thoracic empyema currently affects
over 65,000 patients each year in the US and UK, at an estimated
cost of $500 million to health services [9,10]. Specific microbio-
logical diagnosis is required to guide choice of antibiotic therapy,
and is usually achieved through evaluation of pleural fluid/
exudate and blood cultures. The causative microorganism is,
however, only identified in approximately half of cases. A wide
range of microbes have been isolated from empyema. Common
bacterial pathogens include Streptococcus milleri group species,
Streptococcus pneumoniae, methicillin-sensitive Staphylococcus aureus
(MSSA) and the Enterobacteriaceae group [11,12]. Worldwide,
Mycobacterium tuberculosis (TB) is one of the most important causes
of pleural infection, often associated with HIV co-infection
[1,13,14]. In the United Kingdom, there is no routine screening
for TB in patients presenting with empyema.
The treatment of empyema includes protracted courses of
various single and multiple antibiotics. The majority require
surgical drainage, which necessitates prolonged inpatient hospital
admission and substantial costs for service providers [1,5,15,16].
The overall case fatality remains high and there is a need to
identify factors that could improve treatment outcomes. These
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include rapid identification of causative microorganisms and
administration of pathogen-specific therapy; determination of
optimal surgical interventions; and improved characterisation of
risk factors, clinical features and biomarkers for detecting patients
with poor prognosis. We aimed to identify the clinical character-
istics, risk factors, microbial aetiology, operative management and
outcomes, and predictors of early mortality of empyema cases
presenting to a referral cardiothoracic centre in the UK, to
provide informed guidance on developing improved management
and cost-effective service delivery.
Methods
IRB/Ethics: Data were analyzed anonymously, using publicly
available secondary data, therefore no ethics statement is required
for this work.
Study design: A retrospective study of all patients with
empyema presenting over a period of 12 years (1999–2010).
Study population, review of case notes and creation of
study database
Patients were identified using a validated search strategy [17] by
screening the hospital electronic Clinical Data Repository (CDR).
The case definition of empyema was the presence of pus or other
evidence of active infection in the pleural cavity [1,9]. Inclusion
criteria were: the presence of pleural fluid that was macroscopically
purulent; pleural fluid with positive cultures or Gram/AAFB stain;
pleural fluid pH,7.2 with clinical indicators of infection including
fever, peripheral blood leukocytosis and/or elevated C-reactive
protein (CRP); or histological confirmation of pus in the pleural
cavity. Exclusion criteria were: alternative diagnosis on case note
review; duplicate entry or re-admission for same empyema. The
Heart Hospital only treats adult patients (.18 years).
The following information was obtained and recorded: patient
data, medical and surgical history, clinical characteristics, presence
of underlying risk factors, data from investigations (imaging,
microbiology, histopathology of pleural tissue, biochemistry,
serology, HIV testing, haematology, liver and renal function tests),
medical and surgical treatment, antibiotic usage, and duration of
inpatient admission. The outcomes of management were record-
ed, including all-cause mortality at 28 days and all-cause post-
operative complication rate.
Microbiology
Microbiological data recorded included results from pleural
fluid, pleural tissue, blood and sputum cultures, specific mycobac-
terial and fungal cultures, molecular diagnostic tests and nasal
carriage of methicillin-resistant S. aureus (MRSA). Tuberculous
empyema was diagnosed only if M. tuberculosis bacilli were isolated
from empyema pus and/or tissue. Post-operative wound infection
was classified according to ASEPSIS [18] and CDC [19] criteria.
Definitions of community-acquired versus hospital-
acquired empyema
Infection status was defined as hospital-acquired if the onset of
empyema or underlying pneumonia had occurred$two days after
hospitalization, if the patient had been hospitalized within the
preceding four weeks, or if it arose as a complication of an invasive
thoracic procedure.
Surgical procedures
Procedures used for surgical management of empyema were
recorded.
Statistical analyses
Comparisons were performed using the Mann-Whitney U test
or one-way ANOVA with Bonferroni post-tests for continuous
data, and Fisher’s exact test or x2 test for event frequencies as
appropriate. Probability of 28 day mortality was modelled using
logistic regression; in distributions demonstrating skew log10 values
were used. Univariable and multivariable analyses were per-
formed, although due to the low event frequency of mortality a
multivariable model was fitted that was restricted to three factors
(selected on the basis of significance from univariable analyses).
Statistical analyses were conducted using GraphPad Prism v4.01
(GraphPad Software Inc., San Diego, USA) and STATA Version
10 (StataCorp LP, Texas, USA). A P value ,0.05 was considered
significant.
Results
A total of 406 patients with empyema were identified from 526
initially selected by screening CDR. Table 1 shows the
microbiological and demographic characteristics of these empy-
ema cases. Patients were predominantly male (74.1%, P,0.001,
OR=2.87, 95%CI=2.13–3.85), with a median age of 53 years
(IQR=37–69). Empyema were principally community-acquired
(87.4%, P,0.0001, OR=6.96, 95%CI= 4.89–9.90) and right-
sided (57.4%, P=0.03, OR=1.38, 95%CI= 1.04–1.82); four
patients had bilateral empyema. The majority were loculated
(59.6%, P=0.007, OR=1.48, 95%CI= 1.12–1.95).
Positive cultures were obtained from 229 (56.4%) patients: from
pleural fluid/pus in 174 (42.9%) and peripheral blood in 61
(15.0%). Direct microscopy of pleural fluid/pus for acid and
alcohol fast bacilli was reported in 313 (77.1%) patients,
mycobacterial cultures in 348 (85.7%) and histology of the pleural
specimen in 316 (77.8%). Specific fungal cultures were performed
in 148 (36.5%) patients, and serum cryptococcal antigen tested in
five.
Organisms identified included streptococci (16.3%), staphylococ-
ci (15.5%), Gram-negative organisms (8.9%), anaerobes (5.7%),
pseudomonads (4.4%) and mycobacteria (9.1%); 34 cultures (8.4%)
were polymicrobial (Table 1). There was evidence of gender
difference across the microbiological subgroups (x2=19.12,
P=0.01), with male predominance in all except S. pneumoniae
(Figure 1A). Patients with mycobacterial infection were signifi-
cantly younger (median 38 years, IQR 31–51, P,0.001)
(Figure 1B), but no other age differences were observed. S.
pneumoniae (P,0.0001, OR=18.5, 95%CI=3.92–87.4), S. milleri
group (P=0.03, OR=21.0, 95%CI=0.97–454.3), MSSA
(P=0.03, OR=3.50, 95%CI=1.26–9.73), M. tuberculosis
(P,0.0001, OR=36.00, 95%CI=4.44–291.7), and empyema with
no organism isolated (P,0.0001, OR=16.70, 95%CI=8.27–
33.74) were principally community-acquired; whereas MRSA,
Enterobacteriaceae, anaerobes, Pseudomonas species and polymicrobial
infections were commoner in the hospital-acquired group. There
was no difference between the groups in lateralisation of empyema
but there was evidence of variation in loculation (x2=20.05,
P=0.01), which was more frequent with S. pneumoniae (P=0.02,
OR=3.33, 95%CI=1.25–8.88).
The distribution of risk factors among the 406 patients with
empyema and evidence of their variation between microbiological
groups are shown in Table 2. These included thoracic surgery
and trauma; previous empyema; malnutrition; active sepsis;
diabetes mellitus; use of steroids; homelessness; intravenous drug
misuse; and HIV infection. Individual categories achieving
significance included over-representation of Gram-negative and
anaerobic species in patients with a past history of empyema
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Table 1. Microbiological characteristics of empyema.
Age Male Hospital-acquired
(median, IQR)
All (n = 406) 53 (37–69) 301 (74.1%) 51 (12.6%)***
Gram-Positive Cocci (n = 142, 35.0%)
Streptococci (n = 79, 19.5%)
S. milleri (n = 17, 4.2%) 62 (41–73) 14 (82.4%) 3 (17.6%)
S. pneumoniae (n = 39, 9.6%) 40 (35.5–64) 19 (48.7%)*** 2 (5.1%)***
Other Streptococci (n = 10, 2.5%) 37.5 (33–55.5) 6 (60.0%) 0 (0.0%)*
Enterococci (n = 13, 3.2%) 46 (35–57) 10 (76.9%) 4 (30.8%)
Staphylococci (n = 63, 15.5%)
MSSA (n = 36, 8.9%) 49 (33–70) 31 (86.1%) 8 (22.2%)*
MRSA (n = 27, 6.7%) 60 (36.5–69) 23 (85.2%) 12 (44.4%)
Anaerobes (n = 23, 5.7%) 62 (45.5–73) 17 (73.9%) 6 (26.1%)
Gram-Negative Bacilli (n = 41, 10.1%)
Enterobacteriaceae (n = 23, 5.7%) 54 (36.5–72) 17 (73.9%) 9 (39.1%)
P. aeruginosa (n = 18, 4.4%) 56.5 (43.5–67.25) 14 (77.8%) 5 (27.8%)
Other bacteria (n = 13, 3.2%) 50 (41–63) 10 (76.9%) 3 (23.1%)
Mycobacteria (n = 37, 9.1%) 38 (31–51)*** 28 (75.7%) 1 (2.7%)***
Fungi (n = 9, 2.2%) 50 (35–60) 7 (77.8%) 4 (44.4%)
Polymicrobial (n = 34, 8.4%) 50 (33.5–69.5) 27 (79.4%) 13 (38.2%)
No Organism Identified (n = 177, 44.0%) 56 (40–69) 135 (76.3%) 10 (5.6%)***
Data are n (%) unless otherwise stated. P values for hospital-acquired infection refer to significance in favour of community acquisition.
*P,0.05,
***P,0.001.
doi:10.1371/journal.pone.0030074.t001
Figure 1. Microbiological and demographic characteristics. (A) Variation in gender across microbiological subgroups. (B) Patients with
mycobacterial infections were significantly younger; data shown as median, IQR (boxes) and total range. EC, enterococci; EB, Enterobacteriaceae; Ps,
Pseudomonads. ***P,0.001.
doi:10.1371/journal.pone.0030074.g001
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(P=0.03, OR=3.87, 95%CI= 1.18–12.68); and enterococci
(P=0.05, OR=7.35, 95%CI= 1.31–43.05), Enterobacteriaceae
(P=0.04, OR=4.29, 95%CI= 1.25–14.74), Pseudomonas species
(P=0.04, OR=5.20, 95%CI= 1.25–21.58) and polymicrobial
infection (P=0.007, OR=4.40, 95%CI= 1.59–12.20) in septic
patients. Characteristics of individuals with HIV co-infection are
shown in Table 3; in this group the median CD4 count was 380
cells/mL.
The majority of patients were managed by open thoracotomy
and decortication (n= 277, 68.2%). Video-assisted thoracoscopic
surgery (VATS) was used in 116 (28.6%) patients over the study
period; with 17 (14.7%) converted to open procedures. There was
a significant trend towards an increasing use of VATS over time
(x2= 41.85, P,0.0001; Figure 2A). The median duration of total
hospital admission was nine (6–19) days, and post-procedure
admission was seven (4.68–13) days. Duration of hospital
admission stay was shorter with VATS with a median of seven
(5–13) days in total (P,0.0001) and five days post-procedure (4–
8.5) days (P,0.0001); the corresponding durations for open
thoracotomy were 10 (6.5–21) days and seven (5–14) days
respectively. This was reflected in the trend to briefer admissions
over the course of the study, with median durations of 26 (15–40.5)
days in total and 16.5 (9–21) days post-procedure in 1999 falling to
six (4.5–15.5, P=0.0005) and five (4–9, P=0.003) days respec-
tively in 2010. Admission length also varied across microbiological
group (P,0.0001; Figure 2B), and between community and
hospital acquired empyema. Total duration was protracted in
patients with Enterobacteriaceae (P,0.001) and polymicrobial
infections (P=0.006), and shorter in those in whom no organism
was isolated (P,0.0001). Post-operative admission was prolonged
in patients with MRSA (P,0.0001) or Enterobacteriaceae (P=0.007)
infections. Nosocomial infections were associated with significantly
longer total and post-operative admissions with medians of 17 (8–
35.5, P=0.0006) and eight (5–21, P=0.04) days respectively,
compared to nine (6–17) and six (5–12) days for those acquired in
the community.
The all-cause complication rate was 25.1%, the most frequent
being wound infection. These occurred in 23 (5.7%) patients by
CDC criteria [18,19], in whom 18 were superficial and five were
deep infections, with no significant difference between the open
thoracotomy and VATS groups. Other complications included
unsuccessful procedure/incomplete drainage (4.9%), pneumotho-
rax (3.4%), intrathoracic haemorrhage (3.2%), systemic sepsis
(1.5%), lower respiratory tract infection, cardiac dysrhythmia,
infection at other sites, gastrointestinal haemorrhage, and acute
kidney injury. Patients with complications had prolonged hospital
admissions, with medians of 16 (10–32, P,0.0001) total and 13
(7–22.5, P,0.0001) post-operative days compared with eight (5–
16) and six (4–9) days in those who had an uncomplicated
recovery. The 28 day mortality was 5.7%, with no significant
differences across the microbiological groups, or between open
thoracotomy and VATS. Associations of mortality with clinical
characteristics and blood test variables were evaluated by
univariable and multivariable analyses (Table 4). In univariable
analysis patient age (P=0.006), malnutrition (P=0.001) and co-
morbidity (P=0.01) were predictive of mortality, as were low pre-
operative serum albumin (P=0.01) and haemoglobin (P=0.04),
and high serum alkaline phosphatase (P=0.004) and red cell
distribution width (RDW, P,0.001); haemoglobin and RDW
values were not independent. Other variables including white cell
count, CRP (on admission, or peak value), platelet count and renal
function were not associated with mortality. A p value of 0.1 was
used as the threshold for initial selection of factors considered for
multivariable analysis. Subsequently, given the small number of
events (deaths) among this patient group, a model was developed
limited to three predictors, with age, RDW and alkaline
phosphatase selected for inclusion. A forward selection stepwise
procedure for the multivariable model showed association of
mortality with RDW (P=0.001, OR=1.36 per 1 unit increase,
95%CI=1.14–1.63) and alkaline phosphatase (P=0.03,
OR=2.63 per 1 unit increase in the log10 value, 95%CI= 1.08–
6.44).
Discussion
This is to date the largest single centre series on empyema
described, and shows that empyema remains an important cause
of morbidity, mortality and hospital admissions in the UK. The
results highlight several important points. First, a microbiological
diagnosis was only achieved in just over 50% of 406 patients
studied, highlighting the necessity for development and evaluation
of more sensitive and rapid diagnostics for early identification of
the specific microbial aetiologies. This would guide early targeted
antimicrobial therapy and likely influence clinical outcomes.
Second, it is important to note that is TB is important cause of
empyema and may be easily overlooked: 37 cases were identified
where biological specimens were sent with specific requests for
mycobacterial investigation. Only 313 out of 406 cases of
empyema had mycobacterial staining requested, even though this
hospital has high awareness of TB as a differential diagnosis. Since
the incidence of TB in the UK and elsewhere in Europe is
increasing [13], it now becomes imperative that all patients with
empyema are routinely screened. Third, use of VATS led to
reduced median duration of hospital stay and may therefore
reduce costs of empyema treatment; its cost-effectiveness should
now be evaluated against other medical and surgical treatments.
Finally, raised RDW appeared to be strongly associated with early
Table 2. Distribution of risk factors and evidence of variation
between microbiological groups.
Risk Factor Number of Patients x2 P value
Thoracic Surgery 73 (18.0%) 26.46 0.009
Thoracic Trauma 27 (6.7%) 23.19 0.003
Previous empyema 29 (7.1%) 28.21 0.005
Malnourished 188 (46.3%) 41.47 ,0.0001
Septic 139 (34.2%) 84.32 ,0.0001
Smoker 118 (29.1%) 15.65 0.21
COPD 25 (6.2%) 16.12 0.19
Diabetes Mellitus 33 (8.1%) 25.74 0.01
Malignancy 35 (8.6%) 11.24 0.51
Chemotherapy 17 (4.2%) 15.02 0.24
Thoracic radiotherapy 5 (1.2%) 14.39 0.28
Steroids 50 (12.3%) 34.22 0.0006
Immunosuppressant 32 (7.9%) 11.27 0.51
Homeless 19 (4.7%) 25.3 0.01
Alcohol misuse 60 (14.8%) 18.38 0.10
Intravenous drug user 36 (8.9%) 28.38 0.005
HIV-infected 14 (3.4%) 27.18 0.007
Data are n (%).
P values refer to comparisons between the frequencies of microbial aetiologies
in patients with the risk factor and those in whom it was not present.
doi:10.1371/journal.pone.0030074.t002
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Table 3. Characteristics of patients with HIV infection.
Patient CD4 Viral load Anti-retroviral therapy Organism
(cells/mL) (copies/mL)
1 50 .500,000 No S. pneumoniae
2 340 100 Yes S. pneumoniae
3 Not done Not done No S. pneumoniae
4 630 37,000 No S. pneumoniae
5 430 59,000 No S. pneumoniae
6 890 ,50 No M. tuberculosis
7 180 ,50 Yes M. tuberculosis
8 640 38,000 No M. tuberculosis
9 68 Not done No MSSA
10 Not done Not done Yes H. influenzae
11 570 9,000 Yes Candida species
12 30 14,000 Yes Polymicrobial (milleri-group streptococci,
P. mirabilis, C. albicans, A. fumigatus)
13 420 ,50 Yes None isolated
14 323 ,50 Yes None isolated
doi:10.1371/journal.pone.0030074.t003
Figure 2. Operative management. (A) There was a clear trend to increased use of VATS over the course of the study (P,0.001). (B) Total and post-
operative durations of admission varied across the microbiological subgroups. **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0030074.g002
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mortality. This requires further prospective evaluation as a
biomarker for identifying patients at high risk of early death.
Adoption of all these points would be predicted to lead to shorter
inpatient admissions, improved treatment outcomes and reduced
costs of care in an increasingly resource constrained health service
setting.
Comparison of our study with the UK MIST-1 trial [20] and a
Danish multicentre descriptive series [12] revealed several
commonalities but also important differences. The median age
in our cohort was younger (10 and seven years respectively) and
rates of co-morbidity were correspondingly lower; this may
partially reflect referral bias to our tertiary cardiothoracic centre
for operative management. Our study confirmed a right-sided
predominance of empyema at an approximate ratio of 1.2:1 [9],
which closely follows the normal right:left lung volume ratios [21].
The distribution of causative bacterial organisms identified was
similar to recent series [12,20], except that by contrast with MIST-
1 we observed a lower frequency of milleri-group streptococci and
a corresponding increase in S. pneumoniae.
Male predominance was observed in all microbiological
categories except S. pneumoniae, consistent with its established
epidemiology [22]. The role of male gender as a risk factor for
immunocompromise and trauma may partially explain the
predisposition to staphylococcal, Gram-negative, anaerobic and
mycobacterial infections. The microbiology of nosocomial infec-
tions corresponded with that of other series, in which Klebsiella
species and other Gram-negative organisms, and Pseudomonas
species, were more common in patients with chronic disease
requiring frequent hospitalization [23] and intensive care [24].
Sepsis was predictably more common in Gram-negative and
polymicrobial infections, and less frequent in patients with
tuberculosis or among those in whom no organism could be
isolated, presumably since bacterial loads in the pleural fluid are
likely to be lower with reduced rates of bacteraemia. Patients with
HIV co-infection comprised an important subgroup (3.4%),
despite an earlier contradictory report [25]. The predominance
of S. pneumoniae and M. tuberculosis infections follows the patterns
seen in pneumonia among HIV-infected individuals. The absence
of a clear association with CD4 count is consistent with another
series [26] and might reflect the effects of HIV on innate immunity
beyond those on lymphocyte function [27].
Molecular assays, were only available in the latter part of this
study, however a significant proportion of new diagnoses were
established with their use. Several series illustrate that using assays
Table 4. Association between clinical characteristics and blood tests, and mortality.
Variable Survivors Died Odds ratio p Missing
(95% CI) values
Clinical Characteristics
Age (years) 52 (36–68) 65 (52–73) 1.441 (1.11–1.87) 0.006 0
Male gender 286 (74.7%) 15 (65.2%) 0.64 (0.26–1.55) 0.318 0
Smoker 110 (35.7%) 8 (40.0%) 1.2 (0.48–302.00) 0.699 78
Malnourished 166 (43.6%) 22 (95.6%) 28.5 (3.80–213.50) 0.001 2
Co-morbidities 76 (19.8%) 10 (43.5%) 3.11 (1.31–7.36) 0.01 0
Blood tests
Alanine transaminase (IU/L) 25 (16–44) 35 (18–59) 1.332 (0.74–2.42) 0.342 99
Albumin (g/L) 32 (27–38) 27 (24–32) 0.92 (0.86–0.98) 0.014 89
Alkaline phosphatase (IU/L) 114 (86–172) 151 (125–262) 3.412 (1.48–7.84) 0.004 91
APTT (sec) 35 (32–40) 37 (34–40) 1.02 (0.97–1.06) 0.452 85
Bilirubin (mmol/L) 7 (5–10) 7 (4–13) 1.102 (0.48–2.51) 0.823 96
Creatinine (mmol/L) 68 (56–84) 69 (52–99) 1.562 (0.57–4.24) 0.387 58
CRP, admission (mg/L) 100 (34–206) 87 (44–208) 0.993 (0.96–1.04) 0.960 48
CRP, peak (mg/L) 225 (132–301) 205 (136–312) 1.003 (0.96–1.04) 0.954 41
Haemoglobin (g/dL) 11.1 (9.9–12.4) 10.5 (9.4–11.3) 0.76 (0.59–0.98) 0.038 10
INR 1.04 (0.99–1.12) 1.04 (0.98–1.17) 1.014 (0.81–1.27) 0.917 75
Mean platelet volume (fL) 9.5 (8.9–10.1) 9.9 (9.1–10.0) 1.004 (0.96–1.05) 0.822 59
Neutrophils (6109/L) 7.0 (5.0–10.3) 7.3 (5.4–10.7) 1.272 (0.56–2.86) 0.563 59
Platelets (6109/L) 430 (314–569) 324 (210–525) 0.765 (0.58–1.00) 0.053 58
PTT (sec) 11.2 (10.7–12.0) 11.6 (10.5–12.3) 1.01 (0.87–1.16) 0.937 72
Red cell distribution width (%) 14.7 (13.7–16.1) 17.1 (15.5–19.4) 1.36 (1.17–1.59) ,0.001 59
Urea (mmol/L) 4.2 (3.3–6.0) 6.8 (3.6–9.5) 2.152 (0.98–4.71) 0.055 59
White cell count (6109/L) 10.2 (7.7–13.6) 10.2 (8.2–13.3) 1.102 (0.39–3.11) 0.85 58
Data shown as n (%) or median (IQR). Odds ratios:
1per 10 years,
2per log10 units,
3per 10 mg/L,
4per 0.1 units,
5per 1006109/L).
doi:10.1371/journal.pone.0030074.t004
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based on 16 S RNA PCR increases the bacteriological diagnostic
yield in empyema by 17–49% [9,28] and concerns that the
infective/inflammatory biochemical milieu in empyema might
contain molecular inhibitors of PCR reactions do not appear
substantiated [29]. Our study also highlighted a high rate of
tuberculous empyema cases; M. tuberculosis was the second most
commonly isolated single pathogen after S. pneumoniae. This reflects
a combination of a high degree of clinical awareness at our
hospital, and patient demographics in our catchment area.
Patients in our study were referred for surgical drainage of pus,
removal of empyema tissue or other intervention, and so
uncomplicated TB pleural disease or tuberculous pulmonary
parenchymal disease with pleural effusions were not included.
Tuberculous effusions and empyema represent increasingly
common presentations of mycobacterial disease in countries of
high incidence, accounting for 4–10% of cases [14], particularly in
the context of HIV co-infection [1]. Direct microscopy and culture
of pleural fluid have diagnostic yields of 10–20% and 25–50%,
respectively [30]. Additionally, pleural biopsy increases diagnostic
yield to approximately 90% [31]. The introduction of rapid
molecular assays for detection of M. tuberculosis DNA in sputum
specimens should be evaluated on empyema pus and tissue and
should be included in management guidelines if their utility is
confirmed [32].
Since its routine introduction in 2002 in our hospital, we
observed a clear trend over time towards increased use of VATS,
which accounted for almost 50% of operations in the final year
analysed. Thoracoscopic surgery is more likely to be successful
with earlier referrals, before empyema enters the organising phase.
Concordant with other studies suggesting that outcomes of
minimally invasive surgery are superior to open procedures
[5,33–35], we found VATS led to shorter median durations of
admissions, but no reduction in overall complication rate or
mortality. We found no evidence of diminished wound infection
rates with VATS in this cohort. This may reflect both an element
of prophylaxis afforded by long-term antibiotic treatment of the
underlying pleural infection (as these would usually possess good
Gram-positive cover), and possibly less active monitoring related
to shorter inpatient hospital stays.
Mortality in our study was low compared to most other series, in
which rates range from 18–60% [3,5,36], potentially reflecting a
combination of patient selection as well as operative experience.
Nonetheless, we were able to identify several clinical variables that
were associated with early post-operative death. These included
low pre-operative haemoglobin, high RDW, low albumin and high
alkaline phosphatase. The association with RDW probably does
not merely reflect dimorphism attendant on the anaemia of
chronic disease, since RDW was a stronger predicator of mortality
than haemoglobin. Elevated RDW has previously been highlight-
ed as an indicator of inflammatory stress, secondary to impaired
iron mobilisation and availability [37], and correlates with disease
activity and/or poor outcome in several chronic conditions
including rheumatoid arthritis [38], inflammatory bowel disease
[39], heart failure [40], and coronary artery disease [41]. A low
albumin may be associated with mortality both as a marker of
malnutrition and, along with elevated alkaline phosphatase, severe
sepsis. Haemoglobin may assume additional importance as it is a
risk factor amenable to correction with blood transfusion, which
should be evaluated prospectively. Of interest, neither white cell
count nor CRP predicted poor outcome, suggesting that while
these variables have utility for monitoring disease activity they do
not identify high risk patients.
The principal limitation of our study was its retrospective design
and selected population, which as such has an implicit degree of
selection bias. In addition, molecular diagnostics were introduced
into practice later and not systematically used. Nonetheless, our
search strategy has previously been formally validated (with a
reported positive predictive value of 90.6%) [17] and these patients
comprise the largest single centre cohort reported to date.
In conclusion, our study confirms and builds upon the
microbiological findings of previous studies, and demonstrates
that since its introduction use of VATS has been associated with
shorter hospital admissions. Furthermore, we identified a number
of prognostic factors predictive of early mortality, including the
novel association with RDW. These should be investigated further
for development of more accurate diagnostic algorithms and
guidelines for management of empyema, which in turn could
improve outcomes and reduce healthcare costs.
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